- T4 laryngeal cancer with good function
Authors: Jonathan J. Beitler, John A. Ridge, Jan Vermorken, Carol R. Bradford, Primoz Strojan, Nabil F. Saba, Carlos Suarez, Juan P. Rodrigo, Alessandra Rinaldo, Amy Y. Chen, et al.
Pages: 1400 - 1403
- Optimal treatment of ovarian cancer
Authors: Jan Vermorken
Pages: 188 - 191
- Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients
Authors: Petr Szturz, Marie Vinches, Eva Remenar, Carla M.L. van Herpen, Cyril Abdeddaim, John S. Stewart, Catherine Fortpied, Jan Vermorken
Pages: 109 - 118
- Larynx preservation clinical trial design: key issues and recommendations: a consensus panel summary
Authors: Jean-Louis Lefebvre, K. Kian Ang, Jan Vermorken, et al.
Pages: 429 - 441
- Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer
Authors: Vincent A. de Weger, Annelies W. Turksma, Quirinus J. M. Voorham, Jan Vermorken, et al.
Pages: 882 - 889
- Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) head and neck
Authors: A. Psyrri, L. Licitra, D. Lacombe, E. Schuuring, W. Budach, M. Ozsahin, R. Knecht, Jan Vermorken
Pages: 1952 - 1960
- Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 1001 randomized phase II trial
Authors: Bojana Pajk, Tanja Cufer, Peter Canney, Paul Ellis, David Cameron, Emmanuel Blot, Jan Vermorken, Robert Coleman, Sandrine Marreaud, Jan Bogaerts, et al.
Pages: 180 - 185
- PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
Authors: Karin Beelen, Mark Opdam, Tesa M. Severson, Jan Vermorken, et al.
- Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer
Authors: Barbara Burtness, Jean P. Bourhis, Jan Vermorken, Kevin J. Harrington, Ezra E. W. Cohen
- Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review
Authors: Primoz Strojan, Jan Vermorken, Jonathan J. Beitler, Nabil F. Saba, Missak, Jr. Haigentz, Paolo Bossi, Francis P. Worden, Johannes A. Langendijk, Avraham Eisbruch, William M. Mendenhall, et al.
Pages: E2151 - E2158